{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:39:30Z","timestamp":1793410770064,"version":"4.5.0"},"reference-count":68,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2026-0012_abs_001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>DILI causes about 50\u202f% of acute liver failures globally, affecting 14\u201319 per 100,000 annually, and is a leading cause of liver failure and drug withdrawals in the USA and Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2026-0012_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study reviewed 60 case reports of drug-induced liver injury from Medline\/PubMed (2015\u20132025) at Kalpana Chawla Government Medical College. Initially, 108 reports were identified using specific criteria, screened independently by two teams, with duplicates and ineligible reports removed for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2026-0012_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This analysis of 60\u00a0drug-induced liver injury case reports from PubMed\/Medline in past decade found that patients averaged 54.6\u00a0years old, with 55\u202f% female. Most cases occurred in the USA, China, and Japan. Jaundice (42\u202f%) and fatigue (34\u202f%) were common symptoms. Hepatocellular injury was most prevalent (45\u202f%). Atorvastatin and Methimazole were frequently implicated drugs, with 75\u202f% involving polypharmacy. Most ADRs occurred within 2.3\u00a0months of treatment initiation. Drug withdrawal was the primary intervention (93\u202f%), resulting in full recovery in 87\u202f% of cases, though 3\u202f% were\u00a0fatal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2026-0012_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Analysis of 60 DILI cases identified risk factors such as age over 55, female sex, high doses, and polypharmacy. Most cases were drug-related; 78\u202f% required hospitalization. Prevention could reduce cases by up to 50\u202f%, with full recovery upon drug withdrawal.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2026-0012","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:01:36Z","timestamp":1777327296000},"page":"315-323","source":"Crossref","is-referenced-by-count":1,"title":["Trends in drug-induced liver injury (DILI): a case report-based analysis of clinical presentation, severity, preventability, seriousness, and outcomes over the last decade"],"prefix":"10.1515","volume":"37","author":[{"given":"Saurav","family":"Misra","sequence":"first","affiliation":[{"name":"Department of Pharmacology , Kalpana Chawla Government Medical College , Karnal , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant Kumar","family":"Kairi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Kalpana Chawla Government Medical College , Karnal , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Kalpana Chawla Government Medical College , Karnal , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babita","family":"Sheoron","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Kalpana Chawla Government Medical College , Karnal , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Kalpana Chawla Government Medical College , Karnal , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Tuteja","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Kalpana Chawla Government Medical College , Karnal , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_001","unstructured":"Sharma, A, Chakraborti, KK, Handa, SS. Anti-hepatotoxic activity of some Indian herbal formulations as compared to silymarin. Fitoterapia 1991;62:229\u201335."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_002","unstructured":"Subramonium, A, Pushpangadan, P. Development of phytomedicines for liver diseases. Ind J Pharmacol 1999;31:166\u201375."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_003","doi-asserted-by":"crossref","unstructured":"Ostapowicz, G, Fontana, RJ, Schiodt, FV, Larson, A, Davron, JT, Steven, HB, et al.. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United\u00a0States. Ann Intern Med 2002;137:947\u201354. https:\/\/doi.org\/10.7326\/0003-4819-137-12-200212170-00007.","DOI":"10.7326\/0003-4819-137-12-200212170-00007"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_004","unstructured":"UpToDate. [Home page in the Internet] Drug-induced liver injury. https:\/\/www.uptodate.com\/contents\/drug-induced-liver-injury [Accessed 11 Nov 2025]."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_005","doi-asserted-by":"crossref","unstructured":"Roy, S, Shah, Z, Chakraborthy, GS. A brief overview of drug-induced liver damage. Egypt J Intern Med. 2024;36. https:\/\/doi.org\/10.1186\/s43162-024-00315-7.","DOI":"10.1186\/s43162-024-00315-7"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_006","doi-asserted-by":"crossref","unstructured":"Lee, WM. Drug-induced acute liver failure. Clin Liver Dis 2013;17:575\u201386. https:\/\/doi.org\/10.1016\/j.cld.2013.07.001.","DOI":"10.1016\/j.cld.2013.07.001"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_007","doi-asserted-by":"crossref","unstructured":"Larrey, D, Pageaux, GP. Drug-induced acute liver failure. Eur J Gastroenterol Hepatol 2005;17:141\u20133. https:\/\/doi.org\/10.1097\/00042737-200502000-00002.","DOI":"10.1097\/00042737-200502000-00002"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_008","doi-asserted-by":"crossref","unstructured":"Fontana, RJ, Hayashi, PH, Gu, J, Reddy, KR, Barnhart, H, Watkins, PB, et al.. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6\u00a0months from onset. Gastroenterology 2014;147:96\u2013108.e4. https:\/\/doi.org\/10.1053\/j.gastro.2014.03.045.","DOI":"10.1053\/j.gastro.2014.03.045"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_009","doi-asserted-by":"crossref","unstructured":"Sgro, C, Clinard, F, Ouazir, K, Chanay, H, Allard, C, Guilleminet, C, et al.. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451\u20135. https:\/\/doi.org\/10.1053\/jhep.2002.34857.","DOI":"10.1053\/jhep.2002.34857"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_010","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rnsson, ES, Bergmann, OM, Bj\u00f6rnsson, HK, Kvaran, RB, Olafsson, S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144:1419\u201325. https:\/\/doi.org\/10.1053\/j.gastro.2013.02.006.","DOI":"10.1053\/j.gastro.2013.02.006"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_011","doi-asserted-by":"crossref","unstructured":"Stevens, JL, Baker, TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009;14:162\u20137. https:\/\/doi.org\/10.1016\/j.drudis.2008.11.009.","DOI":"10.1016\/j.drudis.2008.11.009"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_012","doi-asserted-by":"crossref","unstructured":"Lewis, JH. Hy\u2019s law,\u2019 the \u2018Rezulin Rule,\u2019 and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006;15:221\u20139. https:\/\/doi.org\/10.1002\/pds.1209.","DOI":"10.1002\/pds.1209"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_013","doi-asserted-by":"crossref","unstructured":"Nichols, WG, Steel, HM, Bonny, T, Adkison, K, Curtis, L, Millard, J, et al.. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008;52:858\u201365. https:\/\/doi.org\/10.1128\/aac.00821-07.","DOI":"10.1128\/AAC.00821-07"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_014","doi-asserted-by":"crossref","unstructured":"Lee, WM, Larrey, D, Olsson, R, Lewis, JH, Keisu, M, Auclert, L, et al.. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005;28:351\u201370. https:\/\/doi.org\/10.2165\/00002018-200528040-00006.","DOI":"10.2165\/00002018-200528040-00006"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_015","doi-asserted-by":"crossref","unstructured":"Schnitzer, TJ, Burmester, GR, Mysler, E, Hochberg, MC, Doherty, M, Ehrsam, E, TARGET Study Group, et al.. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665\u201374. https:\/\/doi.org\/10.1016\/s0140-6736(04)16893-1.","DOI":"10.1016\/S0140-6736(04)16893-1"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_016","doi-asserted-by":"crossref","unstructured":"Benza, RL, Barst, RJ, Galie, N, Frost, A, Girgis, RE, Highland, KB, et al.. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 2008;134:775\u201382. https:\/\/doi.org\/10.1378\/chest.07-0767.","DOI":"10.1378\/chest.07-0767"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_017","doi-asserted-by":"crossref","unstructured":"Wysowski, DK, Swartz, L. Adverse drug event surveillance and drug withdrawals in the United\u00a0States, 1969\u20132002: the importance of reporting suspected reactions. Arch Intern Med 2005;165:1363\u20139. https:\/\/doi.org\/10.1001\/archinte.165.12.1363.","DOI":"10.1001\/archinte.165.12.1363"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_018","doi-asserted-by":"crossref","unstructured":"Kullak-Ublick, GA, Andrade, RJ, Merz, M, End, P, Benesic, A, Gerbes, AL, et al.. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017;66:1154\u201364. https:\/\/doi.org\/10.1136\/gutjnl-2016-313369.","DOI":"10.1136\/gutjnl-2016-313369"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_019","unstructured":"David, S, Hamilton, JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev 2010;6:73\u201380."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_020","unstructured":"Francis, P, Navarro, VJ. Drug-Induced Hepatotoxicity. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557535\/ [Accessed 10 Sep 2024]."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_021","doi-asserted-by":"crossref","unstructured":"Horn, JR, Hansten, PD, Chan, LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674\u201380. https:\/\/doi.org\/10.1345\/aph.1h423.","DOI":"10.1345\/aph.1H423"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_022","unstructured":"The U.S Food and drug Administration. Home page in Internet] What is a serious Adverse Event? https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event [Accessed 21 Nov 2025]."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_023","doi-asserted-by":"crossref","unstructured":"Hartwig, SC, Siegel, J, Schneider, PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229\u201331. https:\/\/doi.org\/10.1093\/ajhp\/49.9.2229.","DOI":"10.1093\/ajhp\/49.9.2229"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_024","unstructured":"Schumock, GT, Thornton, JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27:538."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_025","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National institute of diabetes and digestive and kidney diseases. Roussel Uclaf Causality Assessment Method (RUCAM) in Drug Induced Liver Injury; 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548272\/ [Accessed 4 May 2019]."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_026","doi-asserted-by":"crossref","unstructured":"Naranjo, CA, Busto, U, Sellars, EM, Sandor, P, Ruiz, I, Roberts, EA, et al.. Method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239\u201345.","DOI":"10.1038\/clpt.1981.154"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_027","doi-asserted-by":"crossref","unstructured":"Chalasani, N, Bj\u00f6rnsson, E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246\u201359. https:\/\/doi.org\/10.1053\/j.gastro.2010.04.001.","DOI":"10.1053\/j.gastro.2010.04.001"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_028","doi-asserted-by":"crossref","unstructured":"Li, X, Tang, J, Mao, Y. Incidence and risk factors of drug-induced liver injury. Liver Int 2022;42:1999\u20132014. https:\/\/doi.org\/10.1111\/liv.15262.","DOI":"10.1111\/liv.15262"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_029","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rnsson, HK, Bj\u00f6rnsson, ES. Risk factors and prediction for DILI in clinical practice. Expert Opin Drug Metab Toxicol 2025;21:579\u201387. https:\/\/doi.org\/10.1080\/17425255.2025.2468200.","DOI":"10.1080\/17425255.2025.2468200"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_030","doi-asserted-by":"crossref","unstructured":"Suzuki, A, MinjunChen. Epidemiology and risk determinants of drug-induced liver injury: current knowledge and future research needs. Liver Int 2025;45:e16146. https:\/\/doi.org\/10.1111\/liv.16146.","DOI":"10.1111\/liv.16146"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_031","doi-asserted-by":"crossref","unstructured":"Allison, R, Guraka, A, Shawa, IT, Tripathi, G, Moritz, W, Kermanizadeh, A. Drug induced liver injury\u00a0\u2013\u00a0a 2023 update. J\u00a0Toxicol Environ Health B Crit Rev 2023;26:442\u201367. https:\/\/doi.org\/10.1080\/10937404.2023.2261848.","DOI":"10.1080\/10937404.2023.2261848"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_032","unstructured":"David, S, Hamilton, JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev 2010;6:73\u201380."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_033","doi-asserted-by":"crossref","unstructured":"Miller, ED, Abu-Sbeih, H, Chalasani, NP. Drug-induced liver injury in older adults. In: Geriatric Gastroenterology, 2nd ed. cham: Springer International Publishing; 2021:1391\u2013406 pp.","DOI":"10.1007\/978-3-030-30192-7_53"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_034","doi-asserted-by":"crossref","unstructured":"Ngcobo, NN. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review. Clin Pharmacokinet 2025;64:335\u201367. https:\/\/doi.org\/10.1007\/s40262-024-01466-0.","DOI":"10.1007\/s40262-024-01466-0"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_035","doi-asserted-by":"crossref","unstructured":"Wang, Y, Xie, W. Drug-induced liver injury: an overview and update. Gastroenterol Endosc 2023;1:102\u20139. https:\/\/doi.org\/10.1016\/j.gande.2022.11.005.","DOI":"10.1016\/j.gande.2022.11.005"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_036","doi-asserted-by":"crossref","unstructured":"Floreani, A, Bizzaro, D, Shalaby, S, Taliani, G, Burra, P. Special interest group gender in hepatology of the Italian association for the study of the liver (AISF). Sex disparity and drug-induced liver injury. Dig Liver Dis 2023;55:21\u20138. https:\/\/doi.org\/10.1016\/j.dld.2022.06.025.","DOI":"10.1016\/j.dld.2022.06.025"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_037","doi-asserted-by":"crossref","unstructured":"Amacher, D. Female gender as a susceptibility factor for drug-induced liver injury. Hum Exp Toxicol 2014;33:928\u201339. https:\/\/doi.org\/10.1177\/0960327113512860.","DOI":"10.1177\/0960327113512860"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_038","doi-asserted-by":"crossref","unstructured":"Uetrecht, J. Immune-mediated adverse drug reactions. Chem Res Toxicol 2009;22:24\u201334. https:\/\/doi.org\/10.1021\/tx800389u.","DOI":"10.1021\/tx800389u"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_039","doi-asserted-by":"crossref","unstructured":"Richter, A, Anton, SF, Koch, P, Dennett, SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307\u201335; discussion 2306. https:\/\/doi.org\/10.1016\/s0149-2918(03)80222-9.","DOI":"10.1016\/S0149-2918(03)80222-9"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_040","doi-asserted-by":"crossref","unstructured":"Cacabelos, R, Naidoo, V, Corzo, L, Cacabelos, N, Carril, JC. Genophenotypic factors and pharmacogenomics in adverse drug reactions. Int J Mol Sci 2021;22:13302. https:\/\/doi.org\/10.3390\/ijms222413302.","DOI":"10.3390\/ijms222413302"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_041","doi-asserted-by":"crossref","unstructured":"Fisher, K, Vuppalanchi, R, Saxena, R. Drug-induced liver injury. Arch Pathol Lab Med 2015;139:876\u201387. https:\/\/doi.org\/10.5858\/arpa.2014-0214-ra.","DOI":"10.5858\/arpa.2014-0214-RA"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_042","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National institute of diabetes and digestive and kidney diseases. Clinical course and diagnosis of drug induced liver disease; 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548733\/ [Accessed 4 May 2019]."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_043","unstructured":"Idiosyncratic drugs. In: Dictionary of Toxicology. Springer, Singapore. 2024."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_044","doi-asserted-by":"crossref","unstructured":"Lauschke, VM, Ingelman-Sundberg, M. The importance of patient-specific factors for hepatic drug response and toxicity. Int J Mol Sci 2016;17:1714. https:\/\/doi.org\/10.3390\/ijms17101714.","DOI":"10.3390\/ijms17101714"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_045","doi-asserted-by":"crossref","unstructured":"Yang, J, Fern\u00e1ndez-Galilea, M, Mart\u00ednez-Fern\u00e1ndez, L, Gonz\u00e1lez-Muniesa, P, P\u00e9rez-Ch\u00e1vez, A, Mart\u00ednez, JA, et al.. Oxidative stress and non-alcoholic fatty liver disease: effects of Omega-3 fatty acid supplementation. Nutrients 2019;11:872. https:\/\/doi.org\/10.3390\/nu11040872.","DOI":"10.3390\/nu11040872"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_046","doi-asserted-by":"crossref","unstructured":"Delli Bovi, AP, Marciano, F, Mandato, C, Siano, MA, Savoia, M, Vajro, P. Oxidative stress in non-alcoholic fatty liver disease. An updated mini review. Front Med 2021;8:595371. https:\/\/doi.org\/10.3389\/fmed.2021.595371.","DOI":"10.3389\/fmed.2021.595371"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_047","doi-asserted-by":"crossref","unstructured":"Lu, Y, Cederbaum, AI. CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med 2008;44:723\u201338. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2007.11.004.","DOI":"10.1016\/j.freeradbiomed.2007.11.004"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_048","doi-asserted-by":"crossref","unstructured":"Bahirwani, R, Reddy, KR. Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis 2014;34:162\u201371. https:\/\/doi.org\/10.1055\/s-0034-1375957.","DOI":"10.1055\/s-0034-1375957"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_049","doi-asserted-by":"crossref","unstructured":"Block, PD, Assis, DN. Hepatotoxicity of chemotherapy and immune checkpoint inhibitors. Clin Liver Dis 2025;29:483\u2013501. https:\/\/doi.org\/10.1016\/j.cld.2025.03.006.","DOI":"10.1016\/j.cld.2025.03.006"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_050","doi-asserted-by":"crossref","unstructured":"Jiang, Y, Li, R, Li, X, Zhang, N. Risk factors of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis. Curr Oncol 2024;31:7129\u201343. https:\/\/doi.org\/10.3390\/curroncol31110525.","DOI":"10.3390\/curroncol31110525"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_051","doi-asserted-by":"crossref","unstructured":"Mostafa, F, Howle, V, Chen, M. Machine learning to predict drug-induced liver injury and its validation on failed drug candidates in development. Toxics 2024;12:385. https:\/\/doi.org\/10.3390\/toxics12060385.","DOI":"10.3390\/toxics12060385"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_052","doi-asserted-by":"crossref","unstructured":"Xiao, Y, Chen, Y, Ruijian, H, Feng, J, Tianchi, Y, Yang, T. Interpretable machine learning in predicting drug-induced liver injury among tuberculosis patients: model development and validation study. BMC Med Res Methodol 2024;24:92. https:\/\/doi.org\/10.1186\/s12874-024-02214-5.","DOI":"10.1186\/s12874-024-02214-5"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_053","doi-asserted-by":"crossref","unstructured":"Hu, Q, Li, X, Zou, D, He, Z, Xu, T. Development of a warning model for drug-induced liver injury in the older patients. Front Pharmacol 2025;16:1603089. https:\/\/doi.org\/10.3389\/fphar.2025.1603089.","DOI":"10.3389\/fphar.2025.1603089"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_054","doi-asserted-by":"crossref","unstructured":"Danan, G, Benichou, C. Causality assessment of adverse reactions to drugs. Part I: a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J\u00a0Clin Epidemiol 1993;46:1323\u201330. https:\/\/doi.org\/10.1016\/0895-4356(93)90101-6.","DOI":"10.1016\/0895-4356(93)90101-6"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_055","doi-asserted-by":"crossref","unstructured":"Benichou, C, Danan, G, Flahault, A. Causality assessment of adverse reactions to drugs. Part II: an original model for validation of drug causality assessment methods: case reports with positive rechallenge. J\u00a0Clin Epidemiol 1993;46:1331\u20136. https:\/\/doi.org\/10.1016\/0895-4356(93)90102-7.","DOI":"10.1016\/0895-4356(93)90102-7"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_056","doi-asserted-by":"crossref","unstructured":"Danan, G, Teschke, R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 2015;17:14\u201330. https:\/\/doi.org\/10.3390\/ijms17010014.","DOI":"10.3390\/ijms17010014"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_057","doi-asserted-by":"crossref","unstructured":"Kozielewicz, DM, Stalke, P, Skrzypek, J. Drug-induced liver injury. Part I: classification, diagnosis and treatment. Clin Exp Hepatol 2025;11:25\u201333. https:\/\/doi.org\/10.5114\/ceh.2025.148329.","DOI":"10.5114\/ceh.2025.148329"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_058","doi-asserted-by":"crossref","unstructured":"Teschke, R, Danan, G. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993-Mid 2020: a comprehensive analysis. Medicines (Basel) 2020;7:62. https:\/\/doi.org\/10.3390\/medicines7100062.","DOI":"10.3390\/medicines7100062"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_059","doi-asserted-by":"crossref","unstructured":"Chalasani, N, Bonkovsky, HL, Fontana, R, Lee, W, Stolz, A, Talwalkar, J, United\u00a0States Drug Induced Liver Injury Network, et al.. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015;148:1340\u201352.e7. https:\/\/doi.org\/10.1053\/j.gastro.2015.03.006.","DOI":"10.1053\/j.gastro.2015.03.006"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_060","unstructured":"Council for International Organizations of Medical Sciences (CIOMS) [Home page in Internet] Drug-induced liver injury (DILI). Current status and future directions for drug development and the post-market setting. https:\/\/cioms.ch\/wp-content\/uploads\/2020\/06\/CIOMS_DILI_Web_16Jun2020.pdf [Accessed 21 Nov 2025]."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_061","doi-asserted-by":"crossref","unstructured":"Cohen, EB, Patwardhan, M, Raheja, R, Alpers, DH, Andrade, RJ, Avigan, MI, et al.. Drug-induced liver injury in the elderly: consensus statements and recommendations from the IQ-DILI initiative. Drug Saf 2024;47:301\u201319. https:\/\/doi.org\/10.1007\/s40264-023-01390-5.","DOI":"10.1007\/s40264-023-01390-5"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_062","doi-asserted-by":"crossref","unstructured":"Pedraza, L, Laosa, OFD, Fr\u00edas, J, Carnicero, JA, Ram\u00edrez, E, Carnicero, JA, et al.. Drug induced liver injury in geriatric patients detected by a two-hospital prospective pharmacovigilance program: a comprehensive analysis using the roussel uclaf causality assessment method. Front Pharmacol 2021;11:600255. https:\/\/doi.org\/10.3389\/fphar.2020.600255.","DOI":"10.3389\/fphar.2020.600255"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_063","doi-asserted-by":"crossref","unstructured":"Stephens, C, Robles-Diaz, M, Medina-Caliz, I, Garcia-Cortes, M, Ortega-Alonso, A, Sanabria-Cabrera, J, Participating clinical centres, et al.. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI registry. J\u00a0Hepatol 2021;75:86\u201397. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.029.","DOI":"10.1016\/j.jhep.2021.01.029"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_064","doi-asserted-by":"crossref","unstructured":"Licata, A. Adverse drug reactions and organ damage: the liver. Eur J Intern Med 2016;28:9\u201316. https:\/\/doi.org\/10.1016\/j.ejim.2015.12.017.","DOI":"10.1016\/j.ejim.2015.12.017"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_065","doi-asserted-by":"crossref","unstructured":"Stern, S, Wang, H, Sadrieh, N. Microphysiological models for mechanistic-based prediction of idiosyncratic DILI. Cells 2023;12:1476. https:\/\/doi.org\/10.3390\/cells12111476.","DOI":"10.3390\/cells12111476"},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_066","unstructured":"EASL Home of Hepatology. [home page on the Internet] EASL Clinical Practice Guidelines on vascular diseases of the liver. https:\/\/easl.eu\/publication-category\/clinical-practice-guidelines\/ [Accessed 21 Nov 2025]."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_067","unstructured":"The American association of study of liver disease (AASLD). Practice guidelines. [Home page in Internet]. https:\/\/www.aasld.org\/practice-guidelines [Accessed 21 Nov 2025]."},{"key":"2026072111574557569_j_jbcpp-2026-0012_ref_068","unstructured":"The, U. S Food and Drug Administration [Home page in Internet] Guidance for Industry Drug-Induced Liver Injury. Premarketing Clinical Evaluation. https:\/\/www.fda.gov\/media\/116737\/download [Accessed 21 Nov 2025]."}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2026-0012\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2026-0012\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:58:26Z","timestamp":1784635106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2026-0012\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":68,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,7,22]]}},"alternative-id":["10.1515\/jbcpp-2026-0012"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2026-0012","relation":{},"ISSN":["0792-6855","2191-0286"],"issn-type":[{"value":"0792-6855","type":"print"},{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]}}}